ArticleFrontiers in immunology2021
Increased Expression of Extracellular Vesicles Is Associated With the Procoagulant State in Patients With Established Rheumatoid Arthritis.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- The risk of venous thromboembolism in RA.Rheumatology (Oxford, England) · 2026Review
- Plasma metabolomic and lipidomic signatures characteristic of treatment non-response in rheumatoid arthritis.Frontiers in immunology · 2026Article
- Extracellular vesicle-mediated immunomodulation and targeted delivery: breakthroughs and challenges in rheumatoid arthritis therapy.Frontiers in immunology · 2026Review
- Diagnostic and prognostic roles of endothelial- and platelet-derived extracellular vesicles in cardiovascular diseases.Journal of translational medicine · 2025Review
- Newly-diagnosed rheumatoid arthritis patients have elevated levels of plasma extracellular vesicles with protein cargo altered towards inflammatory processes.Scientific reports · 2025Article
- Extracellular microvesicles from patients with Rheumatoid arthritis promote dendritic cell activationFrontiers in immunology · 2025Article
- Phosphatidylserine-blocking nanoparticles inhibit thrombosis without increased bleeding in mice.Journal of thrombosis and haemostasis : JTH · 2025Article
- Low-Grade Activation of the Extrinsic Coagulation Pathway in Patients with Ulcerative Colitis.Digestive diseases and sciences · 2024Article
- The role of complement and extracellular vesicles in the development of pulmonary embolism in severe COVID-19 cases.PloS one · 2024Article
- Updates on the Pathophysiology and Therapeutic Potential of Extracellular Vesicles with Focus on Exosomes in Rheumatoid Arthritis.Journal of inflammation research · 2024Review
- Review
- Small extracellular vesicles have distinct CD81 and CD9 tetraspanin expression profiles in plasma from rheumatoid arthritis patients.Clinical and experimental medicine · 2023Article
- Platelet-Derived Microparticles and Autoimmune Diseases.International journal of molecular sciences · 2023Review
- A Rare Case of Superior Vena Cava Syndrome in a Patient With Rheumatoid Arthritis and IgA Nephropathy.Cureus · 2022Article
- The Role of Platelet-Derived Extracellular Vesicles in Immune-Mediated Thrombosis.International journal of molecular sciences · 2022Review
- Particulate Matter Exposure and Allergic Rhinitis: The Role of Plasmatic Extracellular Vesicles and Bacterial Nasal Microbiome.International journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study sought to identify different subpopulations of extracellular vesicles (EVs) in plasma from female patients with established rheumatoid arthritis (RA) in relation to the activation of coagulation and fibrin formation in these patients. Forty women were included in the study, 20 patients and 20 age-matched healthy controls. The mean disease duration in patients was 13.0 (5.0-25.0) years, with medium to high disease activity despite ongoing treatment with low-dose prednisolone and methotrexate. There were no differences between the investigated groups regarding the presence of traditional cardiovascular risk factors. The concentration of phosphatidylserine-positive (PS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.